Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ustekinumab re-induction therapy in moderately to severely active Crohn's disease has completed, with results posted in September 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Stelara (ustekinumab) (ustekinumab)

Snippet

Sponsor: Janssen-Cilag Ltd. | Conditions: Crohn Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-09-13